Roughly 76% of people with Tourette syndrome report premonitory urges that build before tics, yet the day to day impact is often measured in much broader, changing numbers. From sleep problems affecting about 40% to 50% of people to a 41% mean reduction in tic severity with deep brain stimulation, the statistics span everything from symptoms to treatment outcomes. Let’s look at how common Tourette syndrome is, which comorbidities cluster around it, and what the evidence says about therapies that can actually shift the course.
Key Takeaways
- A systematic review found sleep problems in about 40% to 50% of people with Tourette syndrome
- DSM-5-TR requires both multiple motor tics and at least one vocal tic for Tourette syndrome diagnosis
- Botulinum toxin injections can produce clinically meaningful reductions in focal motor tics; effects typically last around 3–4 months
- 41% mean reduction in tic severity observed with deep brain stimulation in a meta-analysis
- CBIT delivery is associated with reduced tic-related impairment as measured by the Yale Global Tic Severity Scale (YGTSS) in randomized trials
- 35% of patients with Tourette syndrome experience persistent symptoms into adulthood
- Genetic heritability estimates for Tourette syndrome are around 0.6 to 0.7 in family/twin studies
- 8.2% prevalence of tic disorders (broadly) reported among U.S. children in NHIS analyses (Tourette-related burden context)
- In the U.S., 40% of children with special health care needs receive care through Medicaid and/or CHIP
- Telehealth-based CBIT delivery can achieve tic improvements comparable to in-person formats in published clinical implementations
- 41.7% of individuals with Tourette syndrome have at least one comorbid ADHD diagnosis in a systematic review/meta-analysis
- 27.0% of individuals with Tourette syndrome have obsessive-compulsive disorder (OCD) comorbidity in a systematic review/meta-analysis
- 20.0% of people with Tourette syndrome have self-reported depression comorbidity in a systematic review/meta-analysis
- 38% of individuals with Tourette syndrome meet criteria for chronic tic disorder severity associated with moderate-to-severe functional impairment in a clinical cohort study
- 55% of children with Tourette syndrome experience school-related impairment attributable to tics in a large observational study
About half of people with Tourette syndrome face sleep problems, yet therapies like CBIT can meaningfully reduce tics.
Related reading
01 · Category
Clinical Burden2 stats
01
A systematic review found sleep problems in about 40% to 50% of people with Tourette syndrome
02
DSM-5-TR requires both multiple motor tics and at least one vocal tic for Tourette syndrome diagnosis
Interpretation
Clinical Burden Interpretation
From a clinical burden perspective, sleep problems affect roughly 40% to 50% of people with Tourette syndrome, adding a substantial day to day challenge alongside the DSM-5-TR requirement of multiple motor tics plus at least one vocal tic.
02 · Category
Treatment Outcomes8 stats
01
Botulinum toxin injections can produce clinically meaningful reductions in focal motor tics; effects typically last around 3–4 months
02
41% mean reduction in tic severity observed with deep brain stimulation in a meta-analysis
03
CBIT delivery is associated with reduced tic-related impairment as measured by the Yale Global Tic Severity Scale (YGTSS) in randomized trials
04
In a double-blind randomized trial, aripiprazole produced a statistically significant reduction in tic severity scores versus placebo
05
In a randomized trial, risperidone produced greater improvement than placebo on tic severity outcomes
06
The Yale Global Tic Severity Scale (YGTSS) total score ranges from 0 to 100
07
Systematic review evidence indicates behavioral therapy outcomes are sustained over follow-up in many children
08
In a 2019 Cochrane review, behavioral interventions for tics showed evidence of reduced tic severity versus controls
Interpretation
Treatment Outcomes Interpretation
Across Treatment Outcomes, the most consistent trend is that targeted therapies meaningfully lessen tic severity, with botulinum toxin effects lasting about 3 to 4 months, deep brain stimulation yielding a 41% mean reduction, and both CBIT and behavioral interventions showing sustained improvements in YGTSS scores and other measures versus controls.
03 · Category
Epidemiology7 stats
01
35% of patients with Tourette syndrome experience persistent symptoms into adulthood
02
Genetic heritability estimates for Tourette syndrome are around 0.6 to 0.7 in family/twin studies
03
8.2% prevalence of tic disorders (broadly) reported among U.S. children in NHIS analyses (Tourette-related burden context)
04
A 2021 prevalence analysis estimated Tourette syndrome prevalence at about 0.6% in some pediatric cohorts
05
0.6% estimated Tourette syndrome prevalence among U.S. children in a 2019 systematic review/meta-analysis
06
1.3% prevalence of persistent (chronic) motor tic disorder among U.S. children based on a 2015 population-based estimate
07
3.8% prevalence of Tourette syndrome in a large school-based European survey (Sweden) for children/adolescents
Interpretation
Epidemiology Interpretation
Across epidemiology studies, Tourette syndrome affects roughly 0.6% to 0.6% of children, yet up to 35% have symptoms persisting into adulthood, showing that even a relatively small prevalence can translate into a long-term disease burden.
04 · Category
Industry Trends2 stats
01
In the U.S., 40% of children with special health care needs receive care through Medicaid and/or CHIP
02
Telehealth-based CBIT delivery can achieve tic improvements comparable to in-person formats in published clinical implementations
Interpretation
Industry Trends Interpretation
For the Industry Trends angle, the fact that 40% of U.S. children with special health care needs rely on Medicaid and/or CHIP suggests a major opportunity to scale telehealth delivered CBIT, which has shown tic improvements comparable to in person care in clinical implementations.
05 · Category
Comorbidities5 stats
01
41.7% of individuals with Tourette syndrome have at least one comorbid ADHD diagnosis in a systematic review/meta-analysis
02
27.0% of individuals with Tourette syndrome have obsessive-compulsive disorder (OCD) comorbidity in a systematic review/meta-analysis
03
20.0% of people with Tourette syndrome have self-reported depression comorbidity in a systematic review/meta-analysis
04
52% of people with Tourette syndrome report sleep-related difficulties in a systematic review/meta-analysis published in 2022
05
31% of children with tic disorders have comorbid anxiety symptoms significant enough to require clinical attention in a cohort study
Interpretation
Comorbidities Interpretation
Comorbidities are common in Tourette syndrome, with ADHD present in 41.7% and OCD in 27.0% of cases in systematic reviews, while sleep-related difficulties affect 52%, underscoring that many people face multiple overlapping conditions rather than tics alone.
06 · Category
Functional Impact5 stats
01
38% of individuals with Tourette syndrome meet criteria for chronic tic disorder severity associated with moderate-to-severe functional impairment in a clinical cohort study
02
55% of children with Tourette syndrome experience school-related impairment attributable to tics in a large observational study
03
1.6 days per month of missed school/work attributable to tic symptoms reported in a patient-reported outcomes cohort study
04
2.3x higher odds of having anxiety disorders in individuals with Tourette syndrome versus controls in a case-control study
05
76% of individuals with Tourette syndrome report premonitory urges preceding tics in a systematic review
Interpretation
Functional Impact Interpretation
Overall, functional impact is common and meaningful in Tourette syndrome, with 55% of children reporting school impairment from tics and nearly 1.6 days per month missed from school or work, alongside moderate to severe impairment present in 38% of individuals.
07 · Category
Treatment Patterns2 stats
01
52.3% of adults with Tourette syndrome report experiencing at least one psychiatric comorbidity in a cross-sectional study
02
10% of U.S. patients with Tourette syndrome have prior exposure to antipsychotic medications (including atypicals) in an administrative claims analysis
Interpretation
Treatment Patterns Interpretation
Treatment patterns for Tourette syndrome show that psychiatric comorbidities are common, with 52.3% of adults reporting at least one, yet only about 10% of U.S. patients have prior antipsychotic exposure, suggesting relatively limited use of these medications despite frequent co-occurring mental health needs.
08 · Category
Health Economics2 stats
01
$12,450incremental cost-effectiveness ratio (ICER) per QALY for behavioral interventions compared with usual care in a published decision-analytic model
02
$18,000average annual pharmacy costs for antipsychotic medication use among patients with Tourette syndrome in a claims dataset analysis
Interpretation
Health Economics Interpretation
From a health economics perspective, behavioral interventions for Tourette syndrome show a relatively favorable cost-effectiveness at $12,450 per QALY versus usual care, even though antipsychotic medication use is associated with much higher average annual pharmacy costs of $18,000 in claims data.
09 · Category
Policy & Access5 stats
01
14.2% of households in the U.S. report out-of-pocket spending on mental health services exceeding $1,000 annually (context for TS treatment spending burden)
02
1 in 3 adults with a mental health condition does not receive treatment in a 2022 U.S. survey (access barrier relevant to comorbidity care often required in TS)
03
47% of U.S. mental health clinicians report participating in telehealth use in 2023 survey findings
04
0.7% annual increase in the number of U.S. patients diagnosed with Tourette syndrome in claims data between 2018 and 2022
05
62% of patients with chronic neurological conditions reported that treatment delivery via telehealth reduced travel burden in a 2021 patient survey (implementation context for TS behavioral therapy)
Interpretation
Policy & Access Interpretation
With only a 0.7% yearly increase in diagnosed Tourette syndrome patients in U.S. claims from 2018 to 2022, the policy and access picture suggests that treatment barriers like 1 in 3 adults with mental health conditions not receiving care and the high cost burden on families, where 14.2% spend over $1,000 out of pocket, may be limiting identification and consistent access despite telehealth adoption reaching 47% of clinicians.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Tourette Syndrome Statistics. Gitnux. https://gitnux.org/tourette-syndrome-statistics
MLA
Gabrielle Fontaine. "Tourette Syndrome Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/tourette-syndrome-statistics.
Chicago
Gabrielle Fontaine. 2026. "Tourette Syndrome Statistics." Gitnux. https://gitnux.org/tourette-syndrome-statistics.
Sources & references
38 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)